During the last session, Applied Dna Sciences Inc (NASDAQ:APDN)’s traded shares were 1.02 million, with the beta value of the company hitting 0.48. The 52-week high for the APDN share is $11.76, that puts it down -8946.15 from that peak though still a striking 7.69% gain since the share price plummeted to a 52-week low of $0.12. The company’s market capitalization is $7.08M, and the average trade volume was 4.76 million shares over the past three months.
Applied Dna Sciences Inc (APDN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.00. APDN has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.06.
Applied Dna Sciences Inc (NASDAQ:APDN) trade information
Applied Dna Sciences Inc (APDN) registered a 0.23% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.23% in intraday trading to $0.13, hitting a weekly high. The stock’s 5-day price performance is -10.90%, and it has moved by -24.62% in 30 days. Based on these gigs, the overall price performance for the year is -98.85%.
The consensus price target of analysts on Wall Street is $1.5, which implies an increase of 91.33% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1.5 and $1.5 respectively. As a result, APDN is trading at a discount of -1053.85% off the target high and -1053.85% off the low.
Applied Dna Sciences Inc (APDN) estimates and forecasts
In the rating firms’ projections, revenue will increase 53.99% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.19M as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 1.28M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 929.63k and 797.52k respectively. In this case, analysts expect current quarter sales to grow by 27.47% and then jump by 60.00% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 60.68%. While earnings are projected to return 73.63% in 2025.
APDN Dividends
Applied Dna Sciences Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Also, the Mutual Funds coming in first place with the largest holdings of Applied Dna Sciences Inc (APDN) shares are Fidelity Extended Market Index Fund and Fidelity Series Total Market Index Fund . Data provided on Dec 31, 2024 indicates that Fidelity Extended Market Index Fund owns about 286.93 shares. This amounts to just over 0.52 percent of the company’s overall shares, with a $36812.0 market value. The same data shows that the other fund manager holds slightly less at 52.94, or about 0.10% of the stock, which is worth about $6792.0.
